Other languages TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Market Closed - Nasdaq Other stock markets 21:00:00 17/06/2024 BST			5-day change	1st Jan Change
16.57 ^USD	+0.12%		+4.21%	-2.99%

06-13	Los Angeles County Employees Retirement Association Files an Exempt Solicitation Statement with Securities and Exchange Commission	CI
06-11	Transcript : TG Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 01:20 PM

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Los Angeles County Employees Retirement Association Files an Exempt Solicitation Statement with Securities and Exchange Commission	06-13
CalSTRS Files an Exempt Solicitation Statement to Shareholders of TG Therapeutics	06-10
Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	05-01
TG Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-01
TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi	04-18
Tg Therapeutics, Inc. Awards National Contract by the Department of Veterans Affairs for Briumvi as the Preferred Anti-Cd20 for Relapsing Forms of Multiple Sclerosis	04-18
Tg Therapeutics Insider Sold Shares Worth $351,340, According to a Recent SEC Filing	03-13
TG Therapeutics Says Updated Data in Briumvi Study Shows Manageable Safety, Tolerability Profile	03-01
Sector Update: Health Care Stocks Softer Wednesday Afternoon	02-28
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surge	02-28
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surging in Pre-Trade	02-28
TG Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28
TG Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-28
TG Therapeutics to Receive $12.5 Million Milestone Payment for Launch of Briumvi in Europe	02-26
Sector Update: Health Care Stocks Higher in Afternoon Trading	01-10
TG Therapeutics Shares Fall After Reporting Net Product Preliminary Revenues for Briumvi; Provides 2024 Targets	01-10
TG Therapeutics Reports Net Product Preliminary Q4 and 2023 US Revenue for Briumvi; Provides 2024 Targets	01-10
Looming Big Bank Earnings, Inflation Data Fuel Cautiousness, Driving Muted Premarket Action for US Equity Futures	01-10
TG Therapeutics Acquires Worldwide License to Precision BioSciences' Allogeneic CD19 CAR T Cell Therapy Program	01-09
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases	01-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Other languages

Filters